Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LVGN3616 + LVGN6501 + Nab-paclitaxel |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LVGN3616 | LVGN-3616|LVGN 3616|pradusinstobart | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 124 | LVGN3616 is a humanized monoclonal antibody that targets PD-1 (PDCD1), potentially resulting in restoration of T-cell mediated immune response (NCI Thesaurus). | |
LVGN6501 | LVGN 6501|LVGN-6501 | Limited information is currently available on LVGN6501 (Apr 2023). | ||
Nab-paclitaxel | Abraxane | ABI-007|Paclitaxel Protein-bound | Chemotherapy - Taxane 3 | Abraxane (nab-paclitaxel) is an albumin-stablized version of paclitaxel, which binds microtubules and prevents depolymerization, resulting in decreased cell motility and division (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05075993 | Phase I | Bevacizumab + Cyclophosphamide + LVGN3616 + LVGN6051 + LVGN7409 LVGN3616 + LVGN6051 + LVGN7409 + Nab-paclitaxel Bevacizumab + Cyclophosphamide + LVGN3616 + LVGN6051 LVGN3616 + LVGN6501 + Nab-paclitaxel | Study of LVGN3616 and LVGN6501±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | Active, not recruiting | USA | 0 |